Dopaminergic activity in depressed smokers: A positron emission tomography study

Synapse

Volumn 63, Issue 8, 2009, Pages 681-689

  Busto, Usoa E ^a,b   Redden, Laura ^a   Mayberg, Helen ^c   Kapur, Shitij ^a,b   Houle, Sylvain ^a,b   Zawertailo, Laurie A ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

11C raclopride; Comorbidity; Dopamine; Tobacco dependence

Indexed keywords

CARBON 11; DEXAMPHETAMINE; DOPAMINE; RACLOPRIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MOOD; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; SMOKING; TOBACCO DEPENDENCE; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AMPHETAMINE; BINDING, COMPETITIVE; DEPRESSION; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; SINGLE-BLIND METHOD; STATISTICS AS TOPIC; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 67650444349     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20646     Document Type: Article

References (52)

1. Anderson P. 2006. Global use of alcohol, drugs and tobacco. Drug Alcohol Rev 25(6):489-502.
2. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A. 2004. The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54:65-71.
3. Berlin I, Anthenelli RM. 2001. Monoamine oxidases and tobacco smoking. Int J Neuropsychopharmacol 4:33-42.
4. Breslau N, Johnson E. 2000. Predicting smoking cessation and major depression in nicotine-dependent smokers. Am J Public Health 90:1122-1127.
5. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P, Lee GS, Huang J, Hahn EL, Mandelkern MA. 2004. Smoking-induced ventral striatum dopamine release. Am J Psychiatry 161:1211-1218.
6. Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S, Zamora-Paja E, Farahi J, Saxena S, London ED, McCracken JT. 2006. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63:808-816.
7. Cardenas L. 2003. Dopaminergic activity in major depression and nicotine dependence. Toronto: University of Toronto.
8. Cardenas L, Tremblay L, Naranjo C, Herrmann N, Zack M, Busto U. 2002. Brain reward system activity in major depression and comorbid nicotine dependence. J Pharmacol Exp Therapeut 302:1265-1271.
9. Cardenas L, Houle S, Kapur S, Busto UE. 2004. Oral d-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. Synapse 51:27-31.
10. Centers for Disease Control and Prevention. 2006. Tobacco use among adults-United States, 2005. Morb Mortal Weekly Rep 55:1145-1151.
11. 2 receptors in depression measured with single photon emission computed tomography. Biological Psychiatry 35:128-132.
12. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
13. Drevets WC. 2000. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 126:413-431.
14. Drevets WC. 2003. Neuroimaging abnormalities in the amygdala in mood disorders. Ann N Y Acad Sci 985:420-444.
15. Fergusson DM, Goodwin RD, Horwood LJ. 2003. Major depression and cigarette smoking: results of a 21-year longitudinal study. Psychol Med 33:1357-1367.
16. Fischman MW, Foltin RW. 1991. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 86:1563-1570.
17. Fowler JS, Logan J, Wang GJ, Volkow ND, Telang F, Zhu W, Franceschi D, Pappas N, Ferrieri R, Shea C, Garza V, Xu Y, Schlyer D, Gatley SJ, Ding YS, Alexoff D, Warner D, Netusil N, Carter P, Jayne M, King P, Vaska P. 2003. Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci USA 100:11600-11605.
18. Fowler JS, Logan J, Wang GJ, Volkow ND, Telang F, Zhu W, Franceschi D, Shea C, Garza V, Xu Y, Ding YS, Alexoff D, Warner D, Netusil N, Carter P, Jayne M, King P, Vaska P. 2005. Comparison of monoamine oxidase a in peripheral organs in nonsmokers and smokers. J Nucl Med 46:1414-1420.
19. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, Johnson J. 1990. Smoking, smoking cessation, and major depression. JAMA 264:1546-1549.
20. Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, Mayberg H. 2004. Modulation of cortical-limbic pathways in major depression: Treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 61:34-41.
21. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
22. Canadian Tobacco Use Monitoring Survey (CTUMS). 2006. Ottawa: Health Canada; 2007. Available: http://www.hc-sc.gc.ca/h1-vs/tobac-tabac/research- recherche/stat/-ctumsesutic-2006/ann-summarysommaire-eng.php
23. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. 1991. The Fagerstrom Test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119-1127.
24. Hirvonen J, Karlsson H, Kajander J, Markkula J, Rasi-Hakala H, Nagren K, Salminen JK, Hietala J. 2008. Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl) 197:581-590.
25. John U, Meyer C, Rumpf HJ, Hapke U. 2004. Smoking, nicotine dependence and psychiatric comorbidity-a population-based study including smoking cessation after three years. Drug Alcohol Depend 76:287-295.
26. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. 2005. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.
27. Kinnunen T, Doherty K, Militello FS, Garvey AJ. 1996. Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol 64:791-798.
28. Ko F, Tallerico T, Seeman P. 2006. Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine. Synapse 60:141-151.
29. Krogh C, editor. 1998. Compendium of Pharmaceuticals and Specialties. Ottawa, ON, Canada: Canadian Pharmaceutical Association.
30. Lammertsma A, Hume S. 1996. Simplified reference tissue model for PET receptor studies. Neuroimage 3(Part 1):153-158.
31. Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A. 2002. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 27:1027-1035.
32. Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR. 2004. Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology 29:259-268.
33. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, Minifie C, Houle S, Hussey D, Kennedy SH. 2001. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12:4121-4125.
34. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N, Wilson AA, Houle S. 2006. Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63:1209-1216.
35. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM. 2007a. The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse 61:637-645.
36. Montgomery AJ, Stokes P, Kitamura Y, Grasby PM. 2007b. Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J Affect Disord 101:113-122.
37. Nestler EJ, Carlezon WA Jr. 2006. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151-1159.
38. Nutt DJ. 2006. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 67(Suppl 6):3-8.
39. 2 receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 50:313-322.
40. Pomerleau OF, Pomerleau CS, Mehringer AM, Snedecor SM, Ninowski R, Sen A. 2005. Nicotine dependence, depression, and gender: characterizing phenotypes based on withdrawal discomfort, response to smoking, and ability to abstain. Nicotine Tob Res 7:91-102.
41. Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S, Zubieta JK. 2007. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 32:450-457.
42. Takahashi H, Fujimura Y, Hayashi M, Takano H, Kato M, Okubo Y, Kanno I, Ito H, Suhara T. 2008. Enhanced dopamine release by nicotine in cigarette smokers: A double-blind, randomized, placebo-controlled pilot study. Int J Neuropsychopharmacol 11:413-417.
43. Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE. 2002. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry 59:409-416.
44. Tsukada H, Miyasato K, Harada N, Nishiyama S, Fukumoto D, Kakiuchi T. 2005. Nicotine modulates dopamine synthesis rate as determined by L-[beta-11C]DOPA: PET studies compared with [11C]raclopride binding in the conscious monkey brain. Synapse 57:120-122.
45. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS, Pappas N, Shea C, Piscani K. 1996. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 20:1594-1598.
46. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N. 1997. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386:830-833.
47. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, Jayne M, Ma Y, Wong C. 2006. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 26:6583-6588.
48. Volkow ND, Fowler JS, Wang GJ, Swanson JM. 2004. Dopamine in drug abuse and addiction: Results from imaging studies and treatment implications. Mol Psychiatry 9:557-569.
49. Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J. 1998. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res 83:149-162.
50. Wang GJ, Volkow ND, Levy AV, Fowler JS, Logan J, Alexoff D, Hitzemann RJ, Schyler DJ. 1996. MR-PET image coregistration for quantitation of striatal dopamine D2 receptors. J Comput Assist Tomogr 20:423-428.
51. 2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16:174-182.
52. White TL, Justice AJ, de Wit H. 2002. Differential subjective effects of d-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73:729-741.